The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
The upcoming state-of-the art 400+ bed facility is set to come up at an approximate cost of Rs 500 crore
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Subscribe To Our Newsletter & Stay Updated
